| 000 | 01881 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513150042.0 | ||
| 264 | 0 | _c19981007 | |
| 008 | 199810s 0 0 eng d | ||
| 022 | _a0031-6970 | ||
| 024 | 7 |
_a10.1007/s002280050455 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKudo, S | |
| 245 | 0 | 0 |
_aInvolvement of human cytochrome P450 3A4 in reduced haloperidol oxidation. _h[electronic resource] |
| 260 |
_bEuropean journal of clinical pharmacology _cMay 1998 |
||
| 300 |
_a253-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAnti-Arrhythmia Agents _xpharmacology |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xpharmacology |
| 650 | 0 | 4 |
_aBiotransformation _xdrug effects |
| 650 | 0 | 4 |
_aBiperiden _xpharmacology |
| 650 | 0 | 4 |
_aCarteolol _xmetabolism |
| 650 | 0 | 4 | _aCell Line, Transformed |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP2D6 _xmetabolism |
| 650 | 0 | 4 | _aCytochrome P-450 CYP2D6 Inhibitors |
| 650 | 0 | 4 | _aCytochrome P-450 CYP3A |
| 650 | 0 | 4 | _aCytochrome P-450 Enzyme Inhibitors |
| 650 | 0 | 4 |
_aCytochrome P-450 Enzyme System _xmetabolism |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aHaloperidol _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxylation _xdrug effects |
| 650 | 0 | 4 |
_aIsoenzymes _xantagonists & inhibitors |
| 650 | 0 | 4 | _aKinetics |
| 650 | 0 | 4 |
_aMicrosomes _xdrug effects |
| 650 | 0 | 4 |
_aMixed Function Oxygenases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aOxidation-Reduction _xdrug effects |
| 650 | 0 | 4 |
_aQuinidine _xpharmacology |
| 650 | 0 | 4 |
_aSparteine _xpharmacology |
| 650 | 0 | 4 |
_aTroleandomycin _xadministration & dosage |
| 700 | 1 | _aOdomi, M | |
| 773 | 0 |
_tEuropean journal of clinical pharmacology _gvol. 54 _gno. 3 _gp. 253-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s002280050455 _zAvailable from publisher's website |
| 999 |
_c9647443 _d9647443 |
||